0.8333
Schlusskurs vom Vortag:
$0.9455
Offen:
$0.93745
24-Stunden-Volumen:
111.76K
Relative Volume:
0.30
Marktkapitalisierung:
$1.95M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-10.38M
KGV:
-0.2187
EPS:
-3.81
Netto-Cashflow:
$-12.45M
1W Leistung:
-17.00%
1M Leistung:
-38.97%
6M Leistung:
-70.46%
1J Leistung:
-93.45%
Avenue Therapeutics Inc Stock (ATXI) Company Profile
Firmenname
Avenue Therapeutics Inc
Sektor
Branche
Telefon
781-652-4500
Adresse
1111 KANE CONCOURSE, BAY HARBOR ISLANDS, NY
Vergleichen Sie ATXI mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
ATXI
Avenue Therapeutics Inc
|
0.83 | 1.95M | 0 | -10.38M | -12.45M | -3.81 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
499.71 | 130.96B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
680.37 | 75.53B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
581.25 | 35.07B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
239.24 | 31.72B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
252.63 | 26.76B | 3.32B | -860.46M | -1.04B | -8.32 |
Avenue Therapeutics Inc Aktie (ATXI) Neueste Nachrichten
Avenue Therapeutics stock hits 52-week low at $0.9 amid downturn - Investing.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Avenue Therapeutics granted Nasdaq extension, faces AnnJi dispute - Investing.com
Avenue Therapeutics Annji Intends To Terminate License Agreement With Co -March 07, 2025 at 04:36 pm EST - Marketscreener.com
Intra-Cellular deal, Axsome settlement drive neurological index recovery - BioWorld Online
Wall Street Analysts Believe Keros Therapeutics (KROS) Could Rally 153.67%: Here's is How to Trade - Nasdaq
SEC Form 424B5 filed by Y-mAbs Therapeutics Inc. - Quantisnow
Avenue Therapeutics, Inc. (NASDAQ:ATXI) Short Interest Down 40.5% in February - Defense World
BriaCell Therapeutics Corp. (NASDAQ:BCTX) Sees Significant Increase in Short Interest - Defense World
KESTRA MEDICAL TECHNOLOGIES, LTD. Prices IPO at $14.00-$16.00 Per Share (KMTS) - Defense World
Short Interest in ArrowMark Financial Corp. (NASDAQ:BANX) Expands By 62.6% - Defense World
American Rebel Holdings, Inc. (NASDAQ:AREB) Sees Large Growth in Short Interest - Defense World
Arbe Robotics Ltd. (NASDAQ:ARBE) Short Interest Up 56.5% in February - Defense World
PTC Therapeutics (NASDAQ:PTCT) Shares Gap Down After Analyst Downgrade - Defense World
Avenue Therapeutics stock hits 52-week low at $1.22 - Investing.com
Avenue Therapeutics stock hits 52-week low at $1.22 By Investing.com - Investing.com South Africa
Avenue Therapeutics (NASDAQ:ATXI) vs. Teva Pharmaceutical Industries (NYSE:TEVA) Head to Head Review - Defense World
Wedbush Lowers Earnings Estimates for Travere Therapeutics - Defense World
The Surprise Surge: How Travere Therapeutics Defied Wall Street Trends - Jomfruland.net
Avenue Therapeutics stock hits 52-week low at $1.5 amid challenges - MSN
ATXIAvenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights - br.ADVFN.com
Sionna Therapeutics Prices Upsized Initial Public Offering - GlobeNewswire
Wall Street Analysts Think Viking Therapeutics (VKTX) Is a Good Investment: Is It? - Yahoo Finance
Here’s Why Third Avenue Small-Cap Value Fund Re-established a Position in Five Point Holdings (FPH) - Yahoo Finance
Protagenic Therapeutics Announces Resolution of Nasdaq Deficiency Notice - ACCESS Newswire
Form 424B3 RAPT Therapeutics, Inc. - StreetInsider.com
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Trajan Group Director Increases Stake Through Options - MSN
Processa Pharmaceuticals stock hits 52-week low at $0.65 - MSN
How Are Things Looking For Zeta Global Holdings Corp (NYSE: ZETA) For The Short Term? - Stocks Register
Park Avenue Securities LLC Buys New Shares in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - Defense World
13,028 Shares in Amicus Therapeutics, Inc. (NASDAQ:FOLD) Acquired by Park Avenue Securities LLC - Defense World
Park Avenue Securities LLC Buys Shares of 1,684 Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - Defense World
Park Avenue Securities LLC Boosts Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - Defense World
Assenagon Asset Management S.A. Buys New Stake in Summit Therapeutics Inc. (NASDAQ:SMMT) - Defense World
Protagenic Therapeutics Reports Fourth Quarter and Full Year 2023 Results - ACCESS Newswire
Assenagon Asset Management S.A. Sells 65,316 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) - Defense World
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
FBIOFortress Biotech, Inc. Latest Stock News & Market Updates - StockTitan
Wall Street-Heavily Traded - WDRB
PLRX (Pliant Therapeutics) Momentum Rank : 7 (As of Jan. 24, 2025) - GuruFocus.com
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Stock Position Decreased by Assenagon Asset Management S.A. - Defense World
Fortune Brands plans Deerfield headquarters expansion, hundreds of new jobs; ‘A great endorsement of Lake County’ - Chicago Tribune
Healthcare Triangle Faces Potential Delisting, Plans Annual Meeting - MSN
Assenagon Asset Management S.A. Cuts Stock Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX) - Defense World
United Therapeutics Co. (NASDAQ:UTHR) Shares Purchased by Park Avenue Securities LLC - Defense World
Assenagon Asset Management S.A. Sells 889,884 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
Another strong year for K Street heading into Trump 2.0, tax fights - POLITICO
Spero Therapeutics (NASDAQ:SPRO) Stock Crosses Below Two Hundred Day Moving Average – Should You Sell? - Defense World
Hennion & Walsh Asset Management Inc. Takes Position in Autolus Therapeutics plc (NASDAQ:AUTL) - Defense World
Assenagon Asset Management S.A. Reduces Stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World
Finanzdaten der Avenue Therapeutics Inc-Aktie (ATXI)
Umsatz
Nettogewinn
Free Cashflow
ENV
Avenue Therapeutics Inc-Aktie (ATXI) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
KRANZLER JAY D | Director |
Nov 05 '24 |
Sale |
2.24 |
61 |
137 |
559 |
KRANZLER JAY D | Director |
Sep 30 '24 |
Buy |
2.50 |
497 |
1,242 |
620 |
KRANZLER JAY D | Director |
Sep 27 '24 |
Buy |
2.40 |
3 |
7 |
123 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):